Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney,Stephen Robinson,Ariane Boumendil,Hervé Finel,Irma Khvedelidze,Hannah Hunter,Xavier Poire,Bruno Lioure,Karl S Peggs,Robin Foà,Srinivas Pillai,Tom Van Meerten,Juan Jose Bargay,Christoph Schmid,Vergote Vibeke,Arnold Ganser,Luca Castagna,Ghulam J Mufti,Silvia Montoto

doi:10.1182/blood-2019-123442

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, Stephen Robinson + Show 17 more

Open Access

https://doi.org/10.1182/blood-2019-123442

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 2

Affiliation: European Society for Blood and Marrow Transplantation, Derriford Hospital, Cliniques Universitaires Saint-Luc, Hôpital Civil, Strasbourg, University College London, Sapienza University of Rome, Royal Stoke University Hospital, University Medical Center Groningen, Hospital Son Llatzer, University Hospital Augsburg, Hannover Medical School, Fondazione Humanitas per la Ricerca, King's College London, Barts Health NHS Trust, St Bartholomew's Hospital

#Advisory Committees #Speakers Bureau + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.